SCHEMBL19086431

SCHEMBL19086431

CCOC(=O)/C(Cl)=N\Nc1ccc(OCC)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 1/20 0.48
KCNQ2 O43526 1/20 0.48
RORC P51449 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
FFAR1 O14842 3/20 0.41
MAPT P10636 3/20 0.41
KYAT1 Q16773 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ATM Q13315 1/20 0.40
P2RX3 P56373 2/20 0.40
TDP1 Q9NUW8 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19086432 1.00 KCNQ3 (0.48) KCNQ3KCNQ2RORCMEN1KMT2A
SCHEMBL17572304 1.00 KCNQ3 (0.48) KCNQ3KCNQ2RORCMEN1KMT2A
SCHEMBL16324087 0.90 MEN1 (0.45) KCNQ3KCNQ2MEN1KMT2AMAPT
SCHEMBL16637228 0.90 MEN1 (0.45) KCNQ3KCNQ2MEN1KMT2AMAPT
SCHEMBL16361973 0.90 MEN1 (0.45) KCNQ3KCNQ2MEN1KMT2AMAPT
SCHEMBL10410692 0.80 MAPT (0.59) MEN1KMT2AMAPTKYAT1NPSR1
SCHEMBL10410691 0.80 MAPT (0.59) MEN1KMT2AMAPTKYAT1NPSR1
SCHEMBL12442232 0.80 MAPT (0.59) MEN1KMT2AMAPTKYAT1NPSR1
SCHEMBL16323357 0.79 MAPT (0.54) MEN1KMT2AMAPTKYAT1NPSR1
SCHEMBL16361950 0.79 MAPT (0.54) MEN1KMT2AMAPTKYAT1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3190111-B1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-05-06 EP disclosed
US-9975893-B2 Pyrazolo[3,4-c]pyridine derivatives CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2018-05-22 US disclosed
US-20170291896-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-10-12 US disclosed
EP-3190111-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291896-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES F11, TFPI, F2 KCNQ3 1872/4885KCNQ2 2344/4885RORC 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.